Vertex Other Operating Expenses vs Net Income From Continuing Ops Analysis

VRTX Stock

USD 450.97 0.60 0.13%

Vertex Pharmaceuticals financial indicator trend analysis is much more than just breaking down Vertex Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vertex Pharmaceuticals is a good investment. Please check the relationship between Vertex Pharmaceuticals Other Operating Expenses and its Net Income From Continuing Ops accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Other Operating Expenses vs Net Income From Continuing Ops

Other Operating Expenses vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vertex Pharmaceuticals Other Operating Expenses account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Vertex Pharmaceuticals' Other Operating Expenses and Net Income From Continuing Ops is 0.93. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Vertex Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Vertex Pharmaceuticals' Other Operating Expenses and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Vertex Pharmaceuticals are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Other Operating Expenses i.e., Vertex Pharmaceuticals' Other Operating Expenses and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vertex Pharmaceuticals. It is also known as Vertex Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income From Continuing Ops

Most indicators from Vertex Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 798.2 M in 2024, whereas Discontinued Operations is likely to drop (861.8 K) in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	6.7B	7.9B	8.6B	9.0B
Total Revenue	7.6B	8.9B	9.9B	10.4B

Gross Profit Total Revenue

Vertex Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Property Plant And Equipment Gross	Net Receivables	Common Stock Total Equity	Common Stock	Other Assets	Long Term Debt
Total Assets		0.29	0.96	0.98	1.0	0.88	-0.98	0.94	0.99	0.99	0.89	0.99	0.21	0.58	0.62	0.59	0.99	1.0	-0.07	0.98	0.94	0.99	0.36	0.37	0.86	0.04
Short Long Term Debt Total	0.29		0.24	0.31	0.26	0.52	-0.17	0.05	0.23	0.33	0.11	0.26	0.62	0.69	0.19	0.65	0.42	0.27	0.34	0.38	0.34	0.24	0.71	0.71	0.15	0.6
Other Current Liab	0.96	0.24		0.98	0.96	0.81	-0.94	0.94	0.95	0.95	0.86	0.95	0.13	0.49	0.67	0.48	0.94	0.96	-0.08	0.95	0.92	0.96	0.29	0.3	0.78	0.05
Total Current Liabilities	0.98	0.31	0.98		0.98	0.84	-0.94	0.94	0.95	0.98	0.84	0.96	0.17	0.51	0.69	0.54	0.97	0.97	-0.06	0.97	0.91	0.97	0.33	0.34	0.82	0.03
Total Stockholder Equity	1.0	0.26	0.96	0.98		0.88	-0.98	0.95	0.99	0.99	0.89	0.99	0.18	0.55	0.61	0.57	0.98	1.0	-0.08	0.97	0.94	0.99	0.34	0.35	0.87	0.01
Property Plant And Equipment Net	0.88	0.52	0.81	0.84	0.88		-0.83	0.72	0.86	0.88	0.76	0.88	0.46	0.79	0.33	0.8	0.91	0.88	-0.07	0.86	0.91	0.86	0.61	0.61	0.75	0.26
Net Debt	-0.98	-0.17	-0.94	-0.94	-0.98	-0.83		-0.94	-1.0	-0.94	-0.96	-0.99	-0.2	-0.55	-0.61	-0.54	-0.96	-0.99	0.1	-0.95	-0.94	-0.99	-0.33	-0.34	-0.84	0.0
Retained Earnings	0.94	0.05	0.94	0.94	0.95	0.72	-0.94		0.94	0.93	0.84	0.93	-0.1	0.34	0.63	0.29	0.89	0.94	-0.07	0.93	0.88	0.93	0.06	0.07	0.79	-0.14
Cash	0.99	0.23	0.95	0.95	0.99	0.86	-1.0	0.94		0.96	0.95	1.0	0.21	0.58	0.61	0.57	0.97	1.0	-0.08	0.96	0.95	0.99	0.35	0.36	0.84	0.02
Non Current Assets Total	0.99	0.33	0.95	0.98	0.99	0.88	-0.94	0.93	0.96		0.83	0.96	0.19	0.54	0.6	0.59	0.98	0.97	-0.05	0.96	0.91	0.97	0.36	0.37	0.88	0.04
Non Currrent Assets Other	0.89	0.11	0.86	0.84	0.89	0.76	-0.96	0.84	0.95	0.83		0.94	0.27	0.58	0.58	0.54	0.88	0.92	-0.11	0.86	0.9	0.94	0.35	0.36	0.75	0.03
Cash And Short Term Investments	0.99	0.26	0.95	0.96	0.99	0.88	-0.99	0.93	1.0	0.96	0.94		0.23	0.6	0.61	0.59	0.98	1.0	-0.1	0.97	0.95	0.99	0.37	0.38	0.85	0.04
Common Stock Shares Outstanding	0.21	0.62	0.13	0.17	0.18	0.46	-0.2	-0.1	0.21	0.19	0.27	0.23		0.65	0.1	0.82	0.3	0.22	0.0	0.2	0.27	0.23	0.97	0.97	0.23	0.6
Non Current Liabilities Total	0.58	0.69	0.49	0.51	0.55	0.79	-0.55	0.34	0.58	0.54	0.58	0.6	0.65		0.06	0.79	0.67	0.59	0.0	0.61	0.66	0.57	0.72	0.73	0.39	0.53
Other Current Assets	0.62	0.19	0.67	0.69	0.61	0.33	-0.61	0.63	0.61	0.6	0.58	0.61	0.1	0.06		0.22	0.62	0.62	0.2	0.63	0.54	0.64	0.18	0.18	0.48	-0.18
Other Stockholder Equity	0.59	0.65	0.48	0.54	0.57	0.8	-0.54	0.29	0.57	0.59	0.54	0.59	0.82	0.79	0.22		0.66	0.58	-0.08	0.55	0.58	0.59	0.87	0.88	0.59	0.41
Total Liab	0.99	0.42	0.94	0.97	0.98	0.91	-0.96	0.89	0.97	0.98	0.88	0.98	0.3	0.67	0.62	0.66		0.99	-0.02	0.98	0.94	0.98	0.46	0.47	0.83	0.12
Total Current Assets	1.0	0.27	0.96	0.97	1.0	0.88	-0.99	0.94	1.0	0.97	0.92	1.0	0.22	0.59	0.62	0.58	0.99		-0.08	0.98	0.95	0.99	0.36	0.37	0.85	0.03
Short Term Debt	-0.07	0.34	-0.08	-0.06	-0.08	-0.07	0.1	-0.07	-0.08	-0.05	-0.11	-0.1	0.0	0.0	0.2	-0.08	-0.02	-0.08		0.02	0.07	-0.07	0.02	0.02	-0.07	-0.13
Accounts Payable	0.98	0.38	0.95	0.97	0.97	0.86	-0.95	0.93	0.96	0.96	0.86	0.97	0.2	0.61	0.63	0.55	0.98	0.98	0.02		0.94	0.96	0.37	0.38	0.81	0.1
Property Plant And Equipment Gross	0.94	0.34	0.92	0.91	0.94	0.91	-0.94	0.88	0.95	0.91	0.9	0.95	0.27	0.66	0.54	0.58	0.94	0.95	0.07	0.94		0.95	0.4	0.41	0.78	0.11
Net Receivables	0.99	0.24	0.96	0.97	0.99	0.86	-0.99	0.93	0.99	0.97	0.94	0.99	0.23	0.57	0.64	0.59	0.98	0.99	-0.07	0.96	0.95		0.36	0.37	0.86	0.02
Common Stock Total Equity	0.36	0.71	0.29	0.33	0.34	0.61	-0.33	0.06	0.35	0.36	0.35	0.37	0.97	0.72	0.18	0.87	0.46	0.36	0.02	0.37	0.4	0.36		1.0	0.34	0.61
Common Stock	0.37	0.71	0.3	0.34	0.35	0.61	-0.34	0.07	0.36	0.37	0.36	0.38	0.97	0.73	0.18	0.88	0.47	0.37	0.02	0.38	0.41	0.37	1.0		0.35	0.6
Other Assets	0.86	0.15	0.78	0.82	0.87	0.75	-0.84	0.79	0.84	0.88	0.75	0.85	0.23	0.39	0.48	0.59	0.83	0.85	-0.07	0.81	0.78	0.86	0.34	0.35		0.01
Long Term Debt	0.04	0.6	0.05	0.03	0.01	0.26	0.0	-0.14	0.02	0.04	0.03	0.04	0.6	0.53	-0.18	0.41	0.12	0.03	-0.13	0.1	0.11	0.02	0.61	0.6	0.01

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Short Long Term Debt Total	577.4M	581.5M	556.7M	561M	808.4M	848.8M
Other Current Liab	1.0B	1.1B	1.7B	2.2B	2.8B	3.0B
Total Current Liabilities	1.2B	1.6B	1.9B	2.4B	3.5B	3.7B
Total Stockholder Equity	6.1B	8.7B	10.1B	13.9B	17.6B	18.5B
Property Plant And Equipment Net	745.1M	958.5M	1.1B	1.1B	1.5B	1.5B
Net Debt	(2.5B)	(5.4B)	(6.2B)	(9.9B)	(9.6B)	(9.1B)
Retained Earnings	(1.9B)	858.7M	3.2B	6.5B	10.1B	10.6B
Cash	3.1B	6.0B	6.8B	10.5B	10.4B	10.9B
Non Current Assets Total	3.7B	3.9B	4.4B	5.5B	8.6B	9.0B
Non Currrent Assets Other	326.9M	662.5M	901.1M	1.3B	796.7M	836.5M
Cash And Short Term Investments	3.8B	6.7B	7.5B	10.8B	11.2B	11.8B
Common Stock Shares Outstanding	260.7M	263.4M	259.9M	259.1M	260.5M	153.1M
Liabilities And Stockholders Equity	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Non Current Liabilities Total	1.0B	1.5B	1.5B	1.8B	1.6B	1.7B
Other Current Assets	213.5M	308.3M	545.8M	553.5M	623.7M	654.9M
Other Stockholder Equity	7.9B	7.9B	6.9B	7.4B	7.4B	7.8B
Total Liab	2.2B	3.1B	3.3B	4.2B	5.1B	5.4B
Total Current Assets	4.6B	7.8B	9.0B	12.7B	14.1B	14.9B
Short Term Debt	30.3M	(275.0M)	80.2M	89.4M	83.7M	87.9M
Accounts Payable	87.6M	155.1M	195M	303.9M	364.9M	383.1M
Property Plant And Equipment Gross	745.1M	958.5M	2.3B	2.5B	2.6B	2.8B
Accumulated Other Comprehensive Income	(2.0M)	(68.5M)	15.9M	800K	(14.3M)	(13.6M)
Net Receivables	633.5M	885.4M	1.1B	1.4B	1.6B	1.6B
Common Stock Total Equity	2.6M	2.6M	2.5M	2.6M	3.0M	1.9M
Common Stock	2.6M	2.6M	2.5M	2.6M	3.0M	2.0M
Other Assets	1.2B	587.0M	986.9M	1.4B	1.6B	1.7B
Short Term Investments	699.0M	670.7M	729.9M	274.5M	849.2M	579.6M
Property Plant Equipment	833.3M	958.5M	1.1B	1.5B	1.7B	1.8B
Other Liab	275.5M	923.4M	902.2M	685.8M	788.7M	828.1M
Current Deferred Revenue	62.3M	191.5M	171.7M	159.6M	170.3M	118.8M
Inventory	167.5M	280.8M	353.1M	460.6M	738.8M	775.7M
Net Tangible Assets	4.7B	7.3B	8.7B	12.2B	14.1B	14.8B
Retained Earnings Total Equity	(1.9B)	858.7M	3.2B	6.5B	7.5B	7.9B
Long Term Debt Total	583.9M	581.6M	538.6M	539.0M	619.9M	632.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Other Operating Expenses vs Net Income From Continuing Ops Analysis

Other Operating Expenses vs Net Income From Continuing Ops

Other Operating Expenses vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Other Operating Expenses

Net Income From Continuing Ops

Vertex Pharmaceuticals fundamental ratios Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Net Receivables	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets